基于处方前置审核系统提高肿瘤专科合理用药水平
Improvement the Level of Rational Drug Use in Cancer Center Based on Pre-Prescription Review System
魏雪 1麦嘉恒 1卢翠婷 1何荣 2刘韬 1潘莹1
作者信息
- 1. 中山大学肿瘤防治中心,华南恶性肿瘤防治全国重点实验室药学部,广东广州 510060
- 2. 中山大学肿瘤防治中心,华南恶性肿瘤防治全国重点实验室信息中心,广东广州 510060
- 折叠
摘要
目的 加强药学服务转型,通过处方前置审核,促进提高肿瘤专科合理用药水平.方法 采用信息化手段,肿瘤药师结合肿瘤专科用药的特点,参与优化扩充适合专科医院用药知识库,加强与临床沟通,建立处方审核反馈机制完善审核知识库内容.结果 全院以抗肿瘤药物为主的处方前置审核软件升级后,门诊及住院处方审核率分别从35.48％升至86.96％、12.34％升至91.88％、医生采纳率从4.35％升至28.13％,事后处方点评合格率从96.10％升至98.91％,尤其是适宜性及超常处方点评合格率显著提高,从70.90％升至98.75％.结论 经整体升级优化处方前置审核系统适用于肿瘤专科医院,一定程度上减少用药错误的发生,规范医生用药行为,提高肿瘤专科合理用药水平.
Abstract
OBJECTIVE To strengthen the transformation of pharmaceutical services,promote the improvement of rational drug use in cancer center through pre-prescription review system.METHODS By means of information technology,tumor pharmacists,in combination with the characteristics of drug use in cancer center,participated in the optimization and expansion of the knowledge base for anti-tumor drugs,strengthened communication with clinic,established a prescription review feedback mechanism,and improved the content of the review knowledge base.RESULTS After the upgrade of the pre-prescription review system mainly for antitumor drugs in the cancer center,the prescription review rate in outpatient and inpatient departments increased from 35.48％to 86.96％and 12.34％to 91.88％,respectively.The doctor's adoption rate increased from 4.35％to 28.13％,the post-prescription review qualified rate increased from 96.10％to 98.91％.In particular,the qualified rate of suitability supernormal prescriptions increased significantly,from 70.90％to 98.75％.CONCLUSION After upgrading and optimization,the pre-prescription review system is applicable to cancer center,which can reduce the occurrence of medication errors to a certain extent,standardize doctors'drug use behaviors,and improve the level of rational drug use in cancer center.
关键词
肿瘤专科/合理用药/处方前置审核/信息化手段Key words
cancer center/rational drug use/pre-prescription review system/information technology引用本文复制引用
基金项目
中国搞癌协会肿瘤临床药学专业委员会肿瘤药事质控标准研究项目(Z19GDZS101)
2021-2022年度国家抗肿瘤药物临床应用监测网肿瘤规范化诊疗中青年基金项目(DSS-YSF2022-06)
出版年
2024
NETL
NSTL
万方数据